vs
Side-by-side financial comparison of NATIONAL RESEARCH CORP (NRC) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $35.2M, roughly 1.6× NATIONAL RESEARCH CORP). NATIONAL RESEARCH CORP runs the higher net margin — 5.1% vs -83.0%, a 88.1% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -4.6%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -0.2%).
National Research Corporation, doing business as NRC Health, is an American healthcare company which provides healthcare products and subscription-based solutions in United States and Canada. It was founded in 1981, and is based in Lincoln, Nebraska.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
NRC vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $57.3M |
| Net Profit | $1.8M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 13.3% | -82.2% |
| Net Margin | 5.1% | -83.0% |
| Revenue YoY | -4.6% | 36.9% |
| Net Profit YoY | -72.6% | -9.6% |
| EPS (diluted) | $49.58 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | $57.3M | ||
| Q3 25 | $34.6M | $51.3M | ||
| Q2 25 | $34.0M | $48.5M | ||
| Q1 25 | $33.6M | $32.7M | ||
| Q4 24 | $36.9M | $41.8M | ||
| Q3 24 | $35.8M | $33.3M | ||
| Q2 24 | $35.0M | $29.1M | ||
| Q1 24 | $35.3M | $26.0M |
| Q4 25 | $1.8M | $-47.5M | ||
| Q3 25 | $4.1M | $-52.9M | ||
| Q2 25 | $-106.0K | $-46.6M | ||
| Q1 25 | $5.8M | $-49.5M | ||
| Q4 24 | $6.6M | $-43.3M | ||
| Q3 24 | $5.7M | $-43.6M | ||
| Q2 24 | $6.2M | $-32.3M | ||
| Q1 24 | $6.4M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 13.3% | -82.2% | ||
| Q3 25 | 22.4% | -102.6% | ||
| Q2 25 | 4.7% | -93.4% | ||
| Q1 25 | 25.6% | -143.7% | ||
| Q4 24 | 26.0% | -98.6% | ||
| Q3 24 | 22.3% | -132.0% | ||
| Q2 24 | 25.3% | -139.2% | ||
| Q1 24 | 24.8% | -538.7% |
| Q4 25 | 5.1% | -83.0% | ||
| Q3 25 | 11.9% | -103.1% | ||
| Q2 25 | -0.3% | -96.1% | ||
| Q1 25 | 17.2% | -151.4% | ||
| Q4 24 | 17.8% | -103.6% | ||
| Q3 24 | 15.9% | -131.2% | ||
| Q2 24 | 17.6% | -110.9% | ||
| Q1 24 | 18.0% | -544.4% |
| Q4 25 | $49.58 | $-0.73 | ||
| Q3 25 | $0.18 | $-0.82 | ||
| Q2 25 | $-0.01 | $-0.75 | ||
| Q1 25 | $0.25 | $-0.81 | ||
| Q4 24 | $0.27 | $-0.71 | ||
| Q3 24 | $0.24 | $-0.73 | ||
| Q2 24 | $0.26 | $-0.55 | ||
| Q1 24 | $0.27 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.1M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $14.0M | $139.1M |
| Total Assets | $134.9M | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.1M | $388.9M | ||
| Q3 25 | $2.2M | $416.1M | ||
| Q2 25 | $5.3M | $291.0M | ||
| Q1 25 | $2.5M | $314.5M | ||
| Q4 24 | $4.2M | $320.6M | ||
| Q3 24 | $3.5M | $298.4M | ||
| Q2 24 | $485.0K | $319.1M | ||
| Q1 24 | $1.7M | $201.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $48.7M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $35.2M | — |
| Q4 25 | $14.0M | $139.1M | ||
| Q3 25 | $14.3M | $148.8M | ||
| Q2 25 | $21.3M | $-11.9M | ||
| Q1 25 | $29.7M | $18.9M | ||
| Q4 24 | $31.3M | $21.7M | ||
| Q3 24 | $34.6M | $11.2M | ||
| Q2 24 | $40.2M | $39.3M | ||
| Q1 24 | $36.9M | $61.6M |
| Q4 25 | $134.9M | $480.2M | ||
| Q3 25 | $135.7M | $506.9M | ||
| Q2 25 | $141.4M | $372.7M | ||
| Q1 25 | $135.2M | $386.7M | ||
| Q4 24 | $132.5M | $392.3M | ||
| Q3 24 | $131.8M | $363.6M | ||
| Q2 24 | $119.1M | $381.8M | ||
| Q1 24 | $120.9M | $258.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.41× | — | ||
| Q2 24 | 0.83× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $7.2M | $-25.4M |
| Free Cash FlowOCF − Capex | $6.1M | — |
| FCF MarginFCF / Revenue | 17.2% | — |
| Capex IntensityCapex / Revenue | 3.2% | — |
| Cash ConversionOCF / Net Profit | 3.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | $15.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.2M | $-25.4M | ||
| Q3 25 | $13.8M | $-26.6M | ||
| Q2 25 | $-1.1M | $-23.3M | ||
| Q1 25 | $6.6M | $-40.4M | ||
| Q4 24 | $6.4M | $-18.8M | ||
| Q3 24 | $9.4M | $-25.2M | ||
| Q2 24 | $6.8M | $-29.1M | ||
| Q1 24 | $12.0M | $-40.7M |
| Q4 25 | $6.1M | — | ||
| Q3 25 | $10.2M | — | ||
| Q2 25 | $-4.1M | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $1.9M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $7.9M | — |
| Q4 25 | 17.2% | — | ||
| Q3 25 | 29.4% | — | ||
| Q2 25 | -12.2% | — | ||
| Q1 25 | 10.9% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 21.8% | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | 22.4% | — |
| Q4 25 | 3.2% | — | ||
| Q3 25 | 10.4% | — | ||
| Q2 25 | 8.8% | — | ||
| Q1 25 | 8.9% | — | ||
| Q4 24 | 12.0% | — | ||
| Q3 24 | 4.5% | — | ||
| Q2 24 | 15.0% | — | ||
| Q1 24 | 11.7% | — |
| Q4 25 | 3.99× | — | ||
| Q3 25 | 3.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
